Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A large scale phase 2 study of Allogeneic Cell Therapy Product, hOMSC200 for Treatment of Diabetic Foot Ulcers (DFU)

Next Previous
Trial Profile

A large scale phase 2 study of Allogeneic Cell Therapy Product, hOMSC200 for Treatment of Diabetic Foot Ulcers (DFU)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HoMSC 200 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use

Most Recent Events

  • 22 Apr 2025 New trial record
  • 09 Apr 2025 According to a CYTORA Media Release, the results of phase 1/2a study of HoMSC-200 would support the company for applying an IND during 2H 2025, that will enable starting a large-scale Phase 2 trial for treating DFUs during 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top